nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—CTSG—uterine cervix—vaginal cancer	0.0231	0.0277	CbGeAlD
Bortezomib—PSMA1—epithelium—vaginal cancer	0.0224	0.0268	CbGeAlD
Bortezomib—CTSG—urethra—vaginal cancer	0.0213	0.0254	CbGeAlD
Bortezomib—CTSG—mammalian vulva—vaginal cancer	0.0202	0.0242	CbGeAlD
Bortezomib—PSMD1—uterine cervix—vaginal cancer	0.0186	0.0223	CbGeAlD
Bortezomib—PSMA1—uterus—vaginal cancer	0.0185	0.0221	CbGeAlD
Bortezomib—PSMD1—urethra—vaginal cancer	0.0171	0.0205	CbGeAlD
Bortezomib—PSMD1—endometrium—vaginal cancer	0.0169	0.0202	CbGeAlD
Bortezomib—PSMA1—female reproductive system—vaginal cancer	0.0166	0.0199	CbGeAlD
Bortezomib—PSMD2—uterine cervix—vaginal cancer	0.0165	0.0198	CbGeAlD
Bortezomib—PSMB8—uterine cervix—vaginal cancer	0.0164	0.0196	CbGeAlD
Bortezomib—PSMD1—mammalian vulva—vaginal cancer	0.0163	0.0195	CbGeAlD
Bortezomib—CTSG—vagina—vaginal cancer	0.0157	0.0187	CbGeAlD
Bortezomib—PSMD1—uterus—vaginal cancer	0.0155	0.0186	CbGeAlD
Bortezomib—PSMD2—urethra—vaginal cancer	0.0152	0.0182	CbGeAlD
Bortezomib—PSMA1—female gonad—vaginal cancer	0.0151	0.0181	CbGeAlD
Bortezomib—PSMB8—urethra—vaginal cancer	0.0151	0.018	CbGeAlD
Bortezomib—PSMD2—endometrium—vaginal cancer	0.0149	0.0179	CbGeAlD
Bortezomib—PSMB8—endometrium—vaginal cancer	0.0148	0.0178	CbGeAlD
Bortezomib—PSMB5—uterine cervix—vaginal cancer	0.0145	0.0173	CbGeAlD
Bortezomib—PSMD2—mammalian vulva—vaginal cancer	0.0144	0.0173	CbGeAlD
Bortezomib—PSMB8—mammalian vulva—vaginal cancer	0.0144	0.0172	CbGeAlD
Bortezomib—PSMD2—uterus—vaginal cancer	0.0138	0.0165	CbGeAlD
Bortezomib—PSMB5—urethra—vaginal cancer	0.0133	0.0159	CbGeAlD
Bortezomib—PSMB5—endometrium—vaginal cancer	0.0131	0.0157	CbGeAlD
Bortezomib—PSMD1—female gonad—vaginal cancer	0.0127	0.0152	CbGeAlD
Bortezomib—PSMB5—mammalian vulva—vaginal cancer	0.0127	0.0152	CbGeAlD
Bortezomib—PSMB1—uterine cervix—vaginal cancer	0.0127	0.0152	CbGeAlD
Bortezomib—PSMD1—vagina—vaginal cancer	0.0126	0.0151	CbGeAlD
Bortezomib—PSMD2—female reproductive system—vaginal cancer	0.0124	0.0148	CbGeAlD
Bortezomib—PSMB2—uterine cervix—vaginal cancer	0.0124	0.0148	CbGeAlD
Bortezomib—PSMB5—uterus—vaginal cancer	0.0121	0.0145	CbGeAlD
Bortezomib—PSMB1—urethra—vaginal cancer	0.0116	0.0139	CbGeAlD
Bortezomib—PSMB1—endometrium—vaginal cancer	0.0115	0.0137	CbGeAlD
Bortezomib—PSMB2—urethra—vaginal cancer	0.0114	0.0136	CbGeAlD
Bortezomib—PSMD2—female gonad—vaginal cancer	0.0113	0.0135	CbGeAlD
Bortezomib—PSMD2—vagina—vaginal cancer	0.0112	0.0134	CbGeAlD
Bortezomib—PSMB8—female gonad—vaginal cancer	0.0112	0.0134	CbGeAlD
Bortezomib—PSMB2—endometrium—vaginal cancer	0.0112	0.0134	CbGeAlD
Bortezomib—PSMB8—vagina—vaginal cancer	0.0111	0.0133	CbGeAlD
Bortezomib—PSMB1—mammalian vulva—vaginal cancer	0.0111	0.0133	CbGeAlD
Bortezomib—PSMB2—mammalian vulva—vaginal cancer	0.0108	0.0129	CbGeAlD
Bortezomib—SLC31A1—uterine cervix—vaginal cancer	0.0107	0.0128	CbGeAlD
Bortezomib—PSMB1—uterus—vaginal cancer	0.0106	0.0126	CbGeAlD
Bortezomib—PSMB2—uterus—vaginal cancer	0.0103	0.0123	CbGeAlD
Bortezomib—PSMB5—female gonad—vaginal cancer	0.00988	0.0118	CbGeAlD
Bortezomib—SLC31A1—urethra—vaginal cancer	0.00984	0.0118	CbGeAlD
Bortezomib—PSMB5—vagina—vaginal cancer	0.00982	0.0118	CbGeAlD
Bortezomib—SLC31A1—endometrium—vaginal cancer	0.00968	0.0116	CbGeAlD
Bortezomib—PSMB1—female reproductive system—vaginal cancer	0.00949	0.0114	CbGeAlD
Bortezomib—SLC31A1—mammalian vulva—vaginal cancer	0.00937	0.0112	CbGeAlD
Bortezomib—PSMB2—female reproductive system—vaginal cancer	0.00926	0.0111	CbGeAlD
Bortezomib—PSMA1—Metabolism of mRNA—EIF4A3—vaginal cancer	0.00884	0.0539	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism of mRNA—EIF4A3—vaginal cancer	0.0088	0.0536	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism of mRNA—EIF4A3—vaginal cancer	0.00876	0.0534	CbGpPWpGaD
Bortezomib—PSMB1—female gonad—vaginal cancer	0.00864	0.0103	CbGeAlD
Bortezomib—PSMB1—vagina—vaginal cancer	0.00859	0.0103	CbGeAlD
Bortezomib—PSMB2—female gonad—vaginal cancer	0.00843	0.0101	CbGeAlD
Bortezomib—PSMB2—vagina—vaginal cancer	0.00838	0.01	CbGeAlD
Bortezomib—PSMB8—Interferon Signaling—EIF4A3—vaginal cancer	0.00813	0.0495	CbGpPWpGaD
Bortezomib—SLC31A1—female reproductive system—vaginal cancer	0.00802	0.0096	CbGeAlD
Bortezomib—PSMA1—Metabolism of RNA—EIF4A3—vaginal cancer	0.00757	0.0461	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism of RNA—EIF4A3—vaginal cancer	0.00753	0.0459	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism of RNA—EIF4A3—vaginal cancer	0.00749	0.0457	CbGpPWpGaD
Bortezomib—SLC31A1—female gonad—vaginal cancer	0.0073	0.00873	CbGeAlD
Bortezomib—SLC31A1—vagina—vaginal cancer	0.00726	0.00868	CbGeAlD
Bortezomib—PSMB5—Metabolism of mRNA—EIF4A3—vaginal cancer	0.0067	0.0408	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism of mRNA—EIF4A3—vaginal cancer	0.0067	0.0408	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism of mRNA—EIF4A3—vaginal cancer	0.0067	0.0408	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism of mRNA—EIF4A3—vaginal cancer	0.00661	0.0403	CbGpPWpGaD
Bortezomib—PSMB8—Interferon alpha/beta signaling—IFNA1—vaginal cancer	0.00653	0.0398	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism of RNA—EIF4A3—vaginal cancer	0.00573	0.035	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism of RNA—EIF4A3—vaginal cancer	0.00573	0.035	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism of RNA—EIF4A3—vaginal cancer	0.00573	0.035	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism of RNA—EIF4A3—vaginal cancer	0.00565	0.0345	CbGpPWpGaD
Bortezomib—PSMB8—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.00543	0.0331	CbGpPWpGaD
Bortezomib—CYP1A1—epithelium—vaginal cancer	0.00367	0.00439	CbGeAlD
Bortezomib—CYP1A1—uterine cervix—vaginal cancer	0.00364	0.00435	CbGeAlD
Bortezomib—CYP2C8—endometrium—vaginal cancer	0.00356	0.00426	CbGeAlD
Bortezomib—CYP1A1—urethra—vaginal cancer	0.00334	0.004	CbGeAlD
Bortezomib—PTGS1—epithelium—vaginal cancer	0.00322	0.00385	CbGeAlD
Bortezomib—PTGS1—uterine cervix—vaginal cancer	0.00319	0.00382	CbGeAlD
Bortezomib—CYP1A1—mammalian vulva—vaginal cancer	0.00318	0.00381	CbGeAlD
Bortezomib—CYP2C19—vagina—vaginal cancer	0.00306	0.00366	CbGeAlD
Bortezomib—PSMB8—Interferon Signaling—IFNA1—vaginal cancer	0.00304	0.0185	CbGpPWpGaD
Bortezomib—CYP1A1—uterus—vaginal cancer	0.00303	0.00363	CbGeAlD
Bortezomib—CYP2C8—female reproductive system—vaginal cancer	0.00295	0.00353	CbGeAlD
Bortezomib—PTGS1—endometrium—vaginal cancer	0.00289	0.00346	CbGeAlD
Bortezomib—PTGS1—mammalian vulva—vaginal cancer	0.0028	0.00334	CbGeAlD
Bortezomib—CYP1A1—female reproductive system—vaginal cancer	0.00272	0.00326	CbGeAlD
Bortezomib—CYP2C8—vagina—vaginal cancer	0.00267	0.00319	CbGeAlD
Bortezomib—PTGS1—uterus—vaginal cancer	0.00266	0.00319	CbGeAlD
Bortezomib—CYP2C9—female reproductive system—vaginal cancer	0.00262	0.00314	CbGeAlD
Bortezomib—CYP1A1—female gonad—vaginal cancer	0.00248	0.00297	CbGeAlD
Bortezomib—CYP1A1—vagina—vaginal cancer	0.00246	0.00295	CbGeAlD
Bortezomib—PTGS1—female reproductive system—vaginal cancer	0.00239	0.00286	CbGeAlD
Bortezomib—PSMA1—Immune System—EIF4A3—vaginal cancer	0.00237	0.0145	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—EIF4A3—vaginal cancer	0.00236	0.0144	CbGpPWpGaD
Bortezomib—PSMA1—Gene Expression—EIF4A3—vaginal cancer	0.00236	0.0144	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—EIF4A3—vaginal cancer	0.00235	0.0143	CbGpPWpGaD
Bortezomib—PSMD1—Gene Expression—EIF4A3—vaginal cancer	0.00235	0.0143	CbGpPWpGaD
Bortezomib—PSMD2—Gene Expression—EIF4A3—vaginal cancer	0.00234	0.0142	CbGpPWpGaD
Bortezomib—PTGS1—female gonad—vaginal cancer	0.00218	0.00261	CbGeAlD
Bortezomib—PTGS1—vagina—vaginal cancer	0.00216	0.00259	CbGeAlD
Bortezomib—PSMB8—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.00203	0.0124	CbGpPWpGaD
Bortezomib—CYP3A4—female reproductive system—vaginal cancer	0.002	0.00239	CbGeAlD
Bortezomib—CYP2D6—female reproductive system—vaginal cancer	0.00197	0.00235	CbGeAlD
Bortezomib—PSMB2—Immune System—EIF4A3—vaginal cancer	0.0018	0.011	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—EIF4A3—vaginal cancer	0.0018	0.011	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—EIF4A3—vaginal cancer	0.0018	0.011	CbGpPWpGaD
Bortezomib—CYP2D6—female gonad—vaginal cancer	0.00179	0.00214	CbGeAlD
Bortezomib—PSMB5—Gene Expression—EIF4A3—vaginal cancer	0.00179	0.0109	CbGpPWpGaD
Bortezomib—PSMB1—Gene Expression—EIF4A3—vaginal cancer	0.00179	0.0109	CbGpPWpGaD
Bortezomib—PSMB2—Gene Expression—EIF4A3—vaginal cancer	0.00179	0.0109	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—EIF4A3—vaginal cancer	0.00177	0.0108	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—EIF4A3—vaginal cancer	0.00176	0.0107	CbGpPWpGaD
Bortezomib—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—vaginal cancer	0.00133	0.0081	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—IFNA1—vaginal cancer	0.000887	0.00541	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—IFNA1—vaginal cancer	0.000883	0.00538	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—IFNA1—vaginal cancer	0.000878	0.00535	CbGpPWpGaD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—vaginal cancer	0.000848	0.00517	CbGpPWpGaD
Bortezomib—PSMB8—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000839	0.00511	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IFNA1—vaginal cancer	0.000672	0.0041	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IFNA1—vaginal cancer	0.000672	0.0041	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IFNA1—vaginal cancer	0.000672	0.0041	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IFNA1—vaginal cancer	0.000663	0.00404	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—IL2—vaginal cancer	0.000367	0.00224	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—IL2—vaginal cancer	0.000365	0.00222	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—IL2—vaginal cancer	0.000363	0.00221	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IL2—vaginal cancer	0.000278	0.00169	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IL2—vaginal cancer	0.000278	0.00169	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IL2—vaginal cancer	0.000278	0.00169	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IL2—vaginal cancer	0.000274	0.00167	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—IL2—vaginal cancer	0.000237	0.00145	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—IL2—vaginal cancer	0.000236	0.00144	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—IL2—vaginal cancer	0.000235	0.00143	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL2—vaginal cancer	0.00018	0.0011	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL2—vaginal cancer	0.00018	0.0011	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL2—vaginal cancer	0.00018	0.0011	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL2—vaginal cancer	0.000177	0.00108	CbGpPWpGaD
